207 lines
44 KiB
HTML
207 lines
44 KiB
HTML
|
<!DOCTYPE html>
|
|||
|
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
|
|||
|
<meta charset="utf-8"/>
|
|||
|
<meta content="pandoc" name="generator"/>
|
|||
|
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
|
|||
|
<title>15 August, 2021</title>
|
|||
|
<style type="text/css">
|
|||
|
code{white-space: pre-wrap;}
|
|||
|
span.smallcaps{font-variant: small-caps;}
|
|||
|
span.underline{text-decoration: underline;}
|
|||
|
div.column{display: inline-block; vertical-align: top; width: 50%;}
|
|||
|
</style>
|
|||
|
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
|
|||
|
<body>
|
|||
|
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
|
|||
|
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
|
|||
|
<ul>
|
|||
|
<li><a href="#from-preprints">From Preprints</a></li>
|
|||
|
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
|
|||
|
<li><a href="#from-pubmed">From PubMed</a></li>
|
|||
|
<li><a href="#from-patent-search">From Patent Search</a></li>
|
|||
|
</ul>
|
|||
|
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
|
|||
|
<ul>
|
|||
|
<li><strong>DECREASED BREADTH OF THE ANTIBODY RESPONSE TO THE SPIKE PROTEIN OF SARS-CoV-2 AFTER VACCINATION</strong> -
|
|||
|
<div>
|
|||
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
The rapid development of vaccines to prevent infection by SARS-CoV-2 virus causing COVID-19 makes necessary to compare the capacity of the different vaccines in terms of development of a protective humoral response. Here, we have used a highly sensitive and reliable flow cytometry method to measure the titers of antibodies of the IgG1 isotype in blood of volunteers after receiving one or two doses of the vaccines being administered in Spain. We took advantage of the multiplexed capacity of the method to measure simultaneously the reactivity of antibodies with the S protein of the original strain Wuhan-1 and the variant B.1.1.7 (Alpha). We found significant differences in the titer of anti-S antibodies produced after a first dose of the vaccines ChAdOx1 nCov-19/AstraZeneca, mRNA-1273/Moderna, BNT162b2/Pfizer- BioNTech and Ad26.COV.S/Janssen. Most important, we found a relative reduction in the reactivity of the sera with the B.1.1.7 versus the Wuhan-1 variant after the second boosting immunization. These data allow to make a comparison of different vaccines in terms of anti-S antibody generation and cast doubts about the convenience of repeatedly immunizing with the same S protein sequence.
|
|||
|
</p>
|
|||
|
</div>
|
|||
|
<div class="article-link article-html-link">
|
|||
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.08.12.21261952v1" target="_blank">DECREASED BREADTH OF THE ANTIBODY RESPONSE TO THE SPIKE PROTEIN OF SARS-CoV-2 AFTER VACCINATION</a>
|
|||
|
</div></li>
|
|||
|
<li><strong>The relationship between fear of COVID-19 and anxiety in Honduran population</strong> -
|
|||
|
<div>
|
|||
|
The purpose of this research was to determine the relationship between fear of COVID-19 and anxiety in the Honduran population. This was made through a quantitative methodology, using the Fear of COVID-19 Scale (FCV-19S) and the Generalized Anxiety Disorder-7 (GAD-7). The sample consisted of 595 Honduran respondents, with a mean age of 25.10 years. The results suggest that female participants reported significantly higher scores in fear of COVID-19 and anxiety than men. A linear regression model determined that fear of COVID-19, sex and age were significant predictors of anxiety scores. The overall model had an r2 of 0.325, with fear of COVID-19 accounting for 29.9% of the variance in GAD-7 scores. The resulting model has a large effect size, f 2= 0.48. The results are discussed considering prior research and their psychosocial implications.
|
|||
|
</div>
|
|||
|
<div class="article-link article-html-link">
|
|||
|
🖺 Full Text HTML: <a href="https://psyarxiv.com/zyw6c/" target="_blank">The relationship between fear of COVID-19 and anxiety in Honduran population</a>
|
|||
|
</div></li>
|
|||
|
<li><strong>Beneficial Effects of novel Aureobasidium Pullulans strains produced Beta-1,3-1,6 Glucans on Interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study</strong> -
|
|||
|
<div>
|
|||
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
Objective: Cytokine storm and Coagulopathy have been implicated as major causes of morbidity and mortality in COVID-19 patients. A black yeast Aureobasidium pullulans AFO 202 strain produced beta 1,3 1,6 glucan has been reported to offer potential immune enhancement and metabolism balancing, as well as mitigation of coagulopathy risks. The N 163 strain produced beta glucan is an efficient anti-inflammatory immune modulator. In this pilot clinical study, we report the beneficial effects of these two beta glucans on the biomarkers for cytokine storm and coagulopathy in COVID-19 patients. Methods: A total of 24 RT PCR positive COVID 19 patients were recruited (Age range: 18~62; 17 males and 7 females). Patients were randomly divided into three groups (Gr): Gr. 1 control (n=8); Gr. 2: AFO-202 beta glucan (n=8); and Gr. 3, a combination of AFO-202 and N-163 beta glucans (n=8). All three groups received the standard care while groups 2 and 3 received additional supplementation of beta glucans for 30 days. In addition to basic clinical parameters, we periodically evaluated D Dimer, IL6, erythrocyte sedimentation rate (ESR), C reactive protein (CRP), the neutrophil to lymphocyte ratio (NLR), the lymphocyte to CRP ratio (LCR) and the leukocyte CRP ratio (LeCR). Results: The duration of hospital stay for all three groups was nearly equivalent. There was no mortality of the subjects in any of the groups. Intermittent oxygen was administered from day of admission for up to four to five days with mask (two to four Lpm) to two subjects in Gr. 2 and one subject in Gr. 3. None of the subjects required ventilation. The D Dimer values in Gr. 1, which was on average 751 ng/ml at baseline, decreased to 143.89 ng/ml on day 15, but increased to 202.5 ng/ml on day 30, which in groups 2 and 3 decreased on day 15 and continued to remain at normal levels until day 30. IL6 levels decreased on day 15 from an average of 7.395 pg/ml to 3.16 pg/ml in the control, 26.18 pg/ml to 6.94 pg/ml in Gr. 2 and 6.25 pg/ml to 5.22 pg/ml in Gr. 3. However, when measured on day 30, in Gr. 1, the IL-6 increased to 55.37 pg/ml while there was only slight marginal increase in Gr. 2 but within normal range, and the levels further decreased to less than 0.5 pg/ml in Gr. 3. The same trend was observed with ESR. LCR and LeCR increased significantly in Gr. 3. NLR decreased significantly in groups 2 and 3. There was no difference in CRP within the groups. Conclusion: In this exploratory study, consumption of Aureobasidium pullulans produced beta glucans for thirty days, results in a significant control of IL6, D Dimer and NLR, a significant increase in LCR, LeCR and marginal control of ESR in COVID 19 patients. As these beta glucans are well known food supplements with decades of a track record for safety, based on these results, we recommend larger multi-centric clinical studies to validate their use as an adjunct in the management of COVID-19 and the ensuing long COVID-19 syndrome.
|
|||
|
</p>
|
|||
|
</div>
|
|||
|
<div class="article-link article-html-link">
|
|||
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.08.09.21261738v1" target="_blank">Beneficial Effects of novel Aureobasidium Pullulans strains produced Beta-1,3-1,6 Glucans on Interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study</a>
|
|||
|
</div></li>
|
|||
|
<li><strong>The impact of seasonal factors on the COVID-19 pandemic waves</strong> -
|
|||
|
<div>
|
|||
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
The daily number of new COVID-19 cases per capita is an important characteristic of the pandemic dynamics indicating the appearance of new waves (e.g., caused by new coronavirus strains) and indicate the effectiveness of quarantine, testing and vaccination. Since this characteristic is very random and demonstrates some weekly period, we will use the 7-days smoothing. The second year of the pandemic allows us to compare its dynamics in the spring and the summer of 2020 with the same period in 2021 and investigate the influence of seasonal factors. We have chosen some northern countries and regions: Ukraine, EU, the UK, USA and some countries located in tropical zone and south semi- sphere: India, Brazil, South Africa and Argentina. The dynamics in these regions was compared with COVID-19 pandemic dynamics in the whole world. Some seasonal similarities are visible only for EU and South Africa. In 2021, the southern countries demonstrated the exponential growth, but northern regions showed some stabilization trends.
|
|||
|
</p>
|
|||
|
</div>
|
|||
|
<div class="article-link article-html-link">
|
|||
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.08.06.21261665v1" target="_blank">The impact of seasonal factors on the COVID-19 pandemic waves</a>
|
|||
|
</div></li>
|
|||
|
<li><strong>A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant Recipients</strong> -
|
|||
|
<div>
|
|||
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
Immunocompromised populations are at high risk for severe COVID-19. Vaccine-induced SARS-CoV-2 antibody responses are attenuated in solid organ transplant recipients (SOTRs), and breakthrough infections are more common. Additional SARS-CoV-2 vaccine doses may increase anti-spike antibody titers in some SOTRs, but whether this results in enhanced neutralizing capability, especially versus novel variants of concern (VOCs) that exhibit immune escape and higher infectivity (e.g., the Delta variant), is unclear. Here, we report that a third dose of a SARS-CoV-2 vaccine increases anti-SARS-CoV-2 spike and RBD IgG levels as well as plasma neutralizing capability versus VOCs, including Delta, in some SOTRs. However, anti-spike IgG and neutralizing capability remained significantly reduced compared to fully vaccinated healthy controls. These findings highlight the need for continued study of strategies to improve protection from COVID-19 in immunosuppressed populations as more SARS-CoV-2 VOCs emerge.
|
|||
|
</p>
|
|||
|
</div>
|
|||
|
<div class="article- link article-html-link">
|
|||
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.08.11.21261914v1" target="_blank">A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant Recipients</a>
|
|||
|
</div></li>
|
|||
|
<li><strong>Associations between COVID-19 Risk Perceptions and Mental Health, Wellbeing, and Risk Behaviours</strong> -
|
|||
|
<div>
|
|||
|
Background: Mental health has worsened, and substance use has increased for some individuals during the coronavirus (COVID-19) pandemic. Cross-sectional studies suggest that COVID-19 risk perceptions are related to mental health and risk behaviours (potentially including substance use). However, longitudinal and genetic data are needed to support stronger inferences regarding whether these associations reflect causal pathways. Methods: Using cross-sectional, longitudinal, and polygenic risk score (PRS) data from the UK Avon Longitudinal Study of Parents and Children (ALSPAC), we examined cross-sectional and prospective associations between COVID-19 risk perceptions and mental health, wellbeing, and risk behaviours. Participants (85% female) were aged between 27-72 years. We used pandemic (April-July 2020) and pre-pandemic (2003-2017) data (ns = 233-5,115). Results: COVID-19 risk perceptions were positively associated with anxiety (OR 2.78, 95% confidence interval [CI] 2.20 to 3.52), depression (OR 1.65, 95% CI 1.24 to 2.18), low wellbeing (OR 1.76, 95% CI 1.45 to 2.13), increased alcohol use (OR 1.46, 95% CI 1.24 to 1.72), and COVID-19 prevention behaviours (ps < .05). Pre-pandemic anxiety (OR 1.64, 95% CI 1.29 to 2.09) and low wellbeing (OR 1.41, 95% CI 1.15 to 1.74) were positively associated with COVID-19 risk perceptions. The depression (b 0.21, 95% CI 0.02 to 0.40) and wellbeing (b -0.29, 95% CI -0.48 to -0.09) PRS were associated with higher and lower COVID-19 risk perceptions, respectively. Conclusions: Poorer mental health and wellbeing are associated with higher COVID-19 risk perceptions, and longitudinal and genetic data suggest that they may play a casual role in COVID-19 risk perceptions.
|
|||
|
</div>
|
|||
|
<div class="article-link article-html-link">
|
|||
|
🖺 Full Text HTML: <a href="https://psyarxiv.com/zup86/" target="_blank">Associations between COVID-19 Risk Perceptions and Mental Health, Wellbeing, and Risk Behaviours</a>
|
|||
|
</div></li>
|
|||
|
<li><strong>Scientists, speak up! Source impacts trust in and intentions to comply with health advice cross-culturally</strong> -
|
|||
|
<div>
|
|||
|
We examined how different types of communication influence people’s responses to health advice. Specifically, we tested whether presenting Covid-19 prevention advice (i.e., washing hands) as either originating from the government or a scientific source would affect people’s trust and intentions to comply with the advice. We also tested the effects of uncertainty framing: We presented the advice as being either certainly or potentially effective in reducing virus spread. To achieve this, we conducted an experiment using largely representative samples (N = 4,561) from the UK, US, Canada, Malaysia, and Taiwan. Overall, across countries, participants found messages more trustworthy when the purported source was science as opposed to government. This effect was stronger for left-wing/liberal participants. Phrasing the advice as certain versus uncertain had little impact on trust and intentions. Together, our findings suggest that health advice should be communicated by scientists rather than governments.
|
|||
|
</div>
|
|||
|
<div class="article-link article-html-link">
|
|||
|
🖺 Full Text HTML: <a href="https://psyarxiv.com/279yg/" target="_blank">Scientists, speak up! Source impacts trust in and intentions to comply with health advice cross-culturally</a>
|
|||
|
</div></li>
|
|||
|
<li><strong>Religious Identity Cues Increase Vaccination Intentions and Trust in Medical Experts among American Christians</strong> -
|
|||
|
<div>
|
|||
|
Containing the COVID-19 pandemic in the U.S. requires mobilizing a large majority of the mass public to vaccinate, but many Americans are hesitant or opposed to vaccination. A significant predictor of vaccine attitudes in the U.S. is religiosity, with more religious individuals expressing more distrust in science and being less likely to get vaccinated. Here, we test whether explicit cues of common religious identity can help medical experts build trust and increase vaccination intentions. In a pre-registered survey experiment conducted with a sample of unvaccinated American Christians (N=1,765), we presented participants with a vaccine endorsement from a prominent medical expert (NIH Director, Francis Collins) and a short essay about doctors’ and scientists’ endorsement of the vaccines. In the common religious identity condition, these materials also highlighted the religious identity of Collins and many medical experts. Unvaccinated Christians in the common identity condition expressed higher trust in medical experts, greater intentions to vaccinate, and greater intentions to promote vaccination to friends and family than those who did not see the common identity cue. These effects were moderated by religiosity, with the strongest effects observed among the most religious participants, and statistically mediated by heightened perceptions of shared values with the medical expert endorsing the vaccine. These findings demonstrate the efficacy of common identity cues for promoting vaccination in a vaccine-hesitant subpopulation. More generally, the results illustrate how trust in science can be built through the invocation of common group identities, even identities often assumed to be in tension with science.
|
|||
|
</div>
|
|||
|
<div class="article-link article-html-link">
|
|||
|
🖺 Full Text HTML: <a href="https://osf.io/preprints/socarxiv/7hrf2/" target="_blank">Religious Identity Cues Increase Vaccination Intentions and Trust in Medical Experts among American Christians</a>
|
|||
|
</div></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 in hospitalized patients in 4 hospitals in San Isidro, Buenos Aires, Argentina</strong> -
|
|||
|
<div>
|
|||
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
In December 2019, a novel illness called coronavirus disease 2019 (COVID 19) was described in China and became pandemic in a few months. The first case was detected in Argentina on March 3, 2020. A multicentre prospective observational cohort study on hospitalized patients with COVID 19 was conducted in 4 hospitals in San Isidro district from March 1, 2020 to October 31. Data was obtained by the attendant physician. 668 patients were included, the median age was 54 years, and 42.7% were female. Male sex and older age were associated with COVID 19 disease and more strongly with severity. Most frequent symptoms were fever and cough followed by dyspnoea, myalgia, odynophagia, headache, anosmia, and diarrhoea. Nonsevere patients had more upper respiratory symptoms while severe patients had mainly lower respiratory symptoms on admission. Most common comorbidities were arterial hypertension, diabetes, and cardiovascular disease. A great proportion of patients had normal thorax X ray and ground-glass opacity in tomography. In severe patients, radiography and tomography had a predominant ground glass pattern, but normal radiography and tomography on presentation were present in 22% and 5.9%, respectively. The absence of fever and normal radiology on admission neither excluded the disease nor further severity. PCR elevation was related with COVID 19 disease and with severity, while lymphopenia was more related with the disease and leukocytosis and thrombocytopenia with severity. 8, 4% of patients were health care workers. The mortality rate was 12.4%, 32.7% in severe patients and 61.2% in ventilated patients. Mortality was higher in the public hospital, probably associated with patients with older age and more comorbidities. All these observations can contribute to the knowledge of this disease in terms of diagnosis and prognosis.
|
|||
|
</p>
|
|||
|
</div></li>
|
|||
|
</ul>
|
|||
|
<div class="article-link article-html-link">
|
|||
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.07.30.21261220v2" target="_blank">COVID-19 in hospitalized patients in 4 hospitals in San Isidro, Buenos Aires, Argentina</a>
|
|||
|
</div>
|
|||
|
<ul>
|
|||
|
<li><strong>MALDI-ToF Protein Profiling as Potential Rapid Diagnostic Platform for COVID-19</strong> -
|
|||
|
<div>
|
|||
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
More than a year after the COVID-19 pandemic has been declared, the need still exists for accurate, rapid, inexpensive and non-invasive diagnostic methods that yield high specificity and sensitivity towards the current and newly emerging SARS-CoV-2 strains. Several studies have since established saliva as a more amenable specimen type for early detection of SARS-CoV-2 as compared to nasopharyngeal swabs. Considering the limitations and high demand for COVID-19 testing, we employed MALDI-ToF mass spectrometry for the analysis of 60 gargle samples from human donors and compared the spectra with their COVID-19 status. Several standards including isolated human serum immunoglobulins and controls such as pre-COVID-19 saliva and heat inactivated SARS-CoV-2 virus were simultaneously analyzed to provide a relative view of the saliva and viral proteome as they would appear in this works methodology. Five potential biomarker peaks were established that demonstrated high concordance with COVID-19 positive individuals. Overall, the agreement of these results with RT-qPCR testing on NP swabs was no less than 90% for the studied cohort, which consisted of young and largely asymptomatic student athletes. From a clinical standpoint, the results from this pilot study are promising and suggest that MALDI-ToF can be used to develop a relatively rapid and inexpensive COVID-19 assay.
|
|||
|
</p>
|
|||
|
</div>
|
|||
|
<div class="article-link article-html-link">
|
|||
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.05.26.21257798v2" target="_blank">MALDI-ToF Protein Profiling as Potential Rapid Diagnostic Platform for COVID-19</a>
|
|||
|
</div></li>
|
|||
|
<li><strong>Screening of cell-virus, cell-cell, gene-gene interactions among kingdoms of life at single cell resolution</strong> -
|
|||
|
<div>
|
|||
|
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) issued a significant and urgent threat to global health. The exact animal origin of SARS-CoV-2 remains obscure and understanding its host range is vital for preventing interspecies transmission of this virus. Previously, we have assessed the target cell profiles of SARS-CoV-2 in pets, livestock, poultry and wild animals. With the reverse zoonotic transmission of SARS-CoV-2 to farm animals. Herein, we expand this investigation to a wider range of animal species and viruses to provide it is urgent to expand the a comprehensive source for large-scale susceptible host screening of potential virus hosts to a larger scale. Therefore, we constructed the single cell atlas for several representative mammalian species (alpaca, hamster, hedgehog, chinchilla etc.), as well as comparative atlas for lung, brain and peripheral blood mononuclear cells (PBMC) for various lineages of animals were constructed, from which we systemically analyzed the virus entry factors for SARS-CoV-2 to identify potential host species. Moreover, to fully apply these resources to the prevention of other infectious diseases, we further evaluated the target cells for 113 viruses over 10 million single cells covering 102 species from mammalians, birds, reptiles, amphibians and invertebrates. Conserved cellular connectomes and regulomes were also identified, with great implication for revealing the fundamental cell-cell and gene-gene cross-talks between these species. Overall, our study could help understand the transmission identify the potential host range and tissue tropism of SARS-CoV-2 and, as well as many other diverse set of viruses and, revealing the host-virus co-evolution footprints and throw light upon the control and prevention of current and future pandemics.
|
|||
|
</div>
|
|||
|
<div class="article-link article- html-link">
|
|||
|
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.08.13.456190v1" target="_blank">Screening of cell-virus, cell-cell, gene-gene interactions among kingdoms of life at single cell resolution</a>
|
|||
|
</div></li>
|
|||
|
<li><strong>A diabetic milieu increases cellular susceptibility to SARS-CoV-2 infections in engineered human kidney organoids and diabetic patients</strong> -
|
|||
|
<div>
|
|||
|
SARS-CoV-2 infections lead to a high risk of hospitalization and mortality in diabetic patients. Why diabetic individuals are more prone to develop severe COVID-19 remains unclear. Here, we established a novel human kidney organoid model that mimics early hallmarks of diabetic nephropathy. High oscillatory glucose exposure resulted in metabolic changes, expansion of extracellular membrane components, gene expression changes determined by scRNAseq, and marked upregulation of angiotensin-converting enzyme 2 (ACE2). Upon SARS-CoV-2 infection, hyperglycemic conditions lead to markedly higher viral loads in kidney organoids compared to normoglycemia. Genetic deletion of ACE2, but not of the candidate receptor BSG/CD147, in kidney organoids demonstrated the essential role of ACE2 in SARS-CoV-2 infections and completely prevented SARS-CoV-2 infection in the diabetogenic microenvironment. These data introduce a novel organoid model for diabetic kidney disease and show that diabetic-induced ACE2 licenses the diabetic kidney to enhanced SARS- CoV-2 replication.
|
|||
|
</div>
|
|||
|
<div class="article-link article-html-link">
|
|||
|
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.08.13.456228v1" target="_blank">A diabetic milieu increases cellular susceptibility to SARS-CoV-2 infections in engineered human kidney organoids and diabetic patients</a>
|
|||
|
</div></li>
|
|||
|
<li><strong>Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant</strong> -
|
|||
|
<div>
|
|||
|
SARS-CoV-2 Delta variant has rapidly replaced the Alpha variant around the world. The mechanism that drives this global replacement has not been defined. Here we report that Delta spike mutation P681R plays a key role in the Alpha- to-Delta variant replacement. In a replication competition assay, Delta SARS-CoV-2 efficiently outcompeted the Alpha variant in human lung epithelial cells and primary human airway tissues. Delta SARS-CoV-2 bearing the Alpha-spike glycoprotein replicated less efficiently than the wild-type Delta variant, suggesting the importance of Delta spike in enhancing viral replication. The Delta spike has accumulated mutation P681R located at a furin cleavage site that separates the spike 1 (S1) and S2 subunits. Reverting the P681R mutation to wild-type P681 significantly reduced the replication of Delta variant, to a level lower than the Alpha variant. Mechanistically, the Delta P681R mutation enhanced the cleavage of the full-length spike to S1 and S2, leading to increased infection via cell surface entry. In contrast, the Alpha spike also has a mutation at the same amino acid (P681H), but the spike cleavage from purified Alpha virions was reduced compared to the Delta spike. Collectively, our results indicate P681R as a key mutation in enhancing Delta variant replication via increased S1/S2 cleavage. Spike mutations that potentially affect furin cleavage efficiency must be closely monitored for future variant surveillance.
|
|||
|
</div>
|
|||
|
<div class="article-link article-html- link">
|
|||
|
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.08.12.456173v1" target="_blank">Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant</a>
|
|||
|
</div></li>
|
|||
|
<li><strong>Secreted SARS-CoV-2 ORF8 modulates the cytokine expression profile of human macrophages</strong> -
|
|||
|
<div>
|
|||
|
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still adapting to its new human host. Attention has focussed on the viral spike protein, but substantial variation has been seen in the ORF8 gene. Here, we show that SARS- CoV-2 ORF8 protein undergoes signal peptide-mediated processing through the endoplasmic reticulum and is secreted as a glycosylated, disulphide-linked dimer. The secreted protein from the prototype SARS-CoV-2 virus had no major effect on viability of a variety of cell types, or on IFN or NF-{kappa}B; signalling. However, it modulated cytokine expression from primary CSF1-derived human macrophages, most notably by decreasing IL-6 and IL-8 secretion. Furthermore, a sequence polymorphism L84S that appeared early in the pandemic associated with the Clade S lineage of virus, showed a markedly different effect, of increasing IL-6 production. We conclude that ORF8 sequence polymorphisms can potentially affect SARS-CoV-2 virulence and should therefore be monitored in sequencing-based surveillance.
|
|||
|
</div>
|
|||
|
<div class="article-link article-html-link">
|
|||
|
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.08.13.456266v1" target="_blank">Secreted SARS-CoV-2 ORF8 modulates the cytokine expression profile of human macrophages</a>
|
|||
|
</div></li>
|
|||
|
<li><strong>Conserved T-cell epitopes predicted by bioinformatics in SARS-COV-2 variants</strong> -
|
|||
|
<div>
|
|||
|
Background: Finding conservative T cell epitopes in the proteome of numerous variants of SARS-COV-2 is required to develop T cell activating SARS-COV-2 capable of inducing T cell responses against SARS-COV-2 variants. Methods: A computational workflow was performed to find HLA restricted CD8+ and CD4+ T cell epitopes among conserved amino acid sequences across the proteome of 474727 SARS-CoV-2 strains. Results: A batch of covserved regions in the amino acid sequences were found in the proteome of the SARS-COV-2 strains. 2852 and 847 peptides were predicted to have high binding affinity to distint HLA class I and class II molecules. Among them, 1456 and 484 peptides are antigenic. 392 and 111 of the antigenic peptides were found in the conseved amino acid sequences. Among the antigenic-conserved peptides, 6 CD8+ T cell epitopes and 7 CD4+ T cell epitopes were identifed. The T cell epitopes could be presented to T cells by high-affinity HLA molecules which are encoded by the HLA alleles with high population coverage. Conclusions: The T cell epitopes are conservative, antigenic and HLA presentable, and could be constructed into SARS-COV-2 vaccines for inducing protective T cell immunity against SARS-COV-2 and their variants.
|
|||
|
</div>
|
|||
|
<div class="article-link article- html-link">
|
|||
|
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.08.12.456182v1" target="_blank">Conserved T-cell epitopes predicted by bioinformatics in SARS-COV-2 variants</a>
|
|||
|
</div></li>
|
|||
|
</ul>
|
|||
|
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
|
|||
|
<ul>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Pulmonary Rehabilitation Post-COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Other: Exercise program (virtual/remote)<br/><b>Sponsors</b>: University of Manitoba; Health Sciences Centre Foundation, Manitoba; Health Sciences Centre, Winnipeg, Manitoba<br/><b>Not yet recruiting</b></p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 “Long Haul” Pulmonary Compromise</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Biological: COVI-MSC; Biological: Placebo<br/><b>Sponsor</b>: Sorrento Therapeutics, Inc.<br/><b>Not yet recruiting</b></p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines in Mozambique</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Biological: BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell); Biological: AZD1222 (replication-deficient Ad type 5 vector expressing full-length spike protein)<br/><b>Sponsors</b>: International Vaccine Institute; The Coalition for Epidemic Preparedness Innovations (CEPI); Instituto Nacional de Saúde (INS), Mozambique; University of Antananarivo; International Centre for Diarrhoeal Disease Research, Bangladesh; Harvard University; Heidelberg University<br/><b>Not yet recruiting</b></p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19</strong> - <b>Condition</b>: COVID-19 Infection<br/><b>Intervention</b>: Drug: Colchcine<br/><b>Sponsor</b>: <br/>
|
|||
|
Asociacion Instituto Biodonostia<br/><b>Active, not recruiting</b></p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: Danicopan; Other: Placebo; Drug: Remdesivir<br/><b>Sponsor</b>: National Institute of Allergy and Infectious Diseases (NIAID)<br/><b>Recruiting</b></p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 Methylene Blue Antiviral Treatment</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Drug: Methylene Blue; Drug: Saline nasal spray<br/><b>Sponsors</b>: Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences; Irkutsk State Medical University<br/><b>Recruiting</b></p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Project FLUx COntact-CoVID-19 Faculty of Medicine Paris-Saclay</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Other: Antigenic tests (on saliva samples); Other: Individual electronic sensor port; Other: Atmospheric measurements of CO2<br/><b>Sponsor</b>: <br/>
|
|||
|
Assistance Publique - Hôpitaux de Paris<br/><b>Not yet recruiting</b></p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)</strong> - <b>Condition</b>: COVID-19 Lower Respiratory Infection<br/><b>Interventions</b>: Biological: AG0302-COVID19 for Intramuscular Injection; Biological: AG0302-COVID19 for Intradermal Injection<br/><b>Sponsors</b>: AnGes, Inc.; Japan Agency for Medical Research and Development<br/><b>Not yet recruiting</b></p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 Administration of Single-Dose Subcutaneous or Intramuscular Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Drug: casirivimab and imdevimab<br/><b>Sponsor</b>: <br/>
|
|||
|
Regeneron Pharmaceuticals<br/><b>Not yet recruiting</b></p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Biological: Placebo; Biological: Inactivated vaccine booster; Biological: mRNA vaccine booster; Drug: Viral vector vaccine booster<br/><b>Sponsors</b>: Universidad del Desarrollo; Ministry of Health, Chile; University of Chile; Pontificia Universidad Catolica de Chile<br/><b>Active, not recruiting</b></p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Relaxation Exercise in Patients With COVID-19</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Other: Relaxation technique<br/><b>Sponsor</b>: Beni- Suef University<br/><b>Completed</b></p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector, Ad5-nCoV) in Adults Living With HIV</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)<br/><b>Sponsors</b>: Fundación Huésped; Canadian Center for Vaccinology; CanSino Biologics Inc.; Hospital Fernandez<br/><b>Recruiting</b></p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Drug: Drug, inhalation<br/><b>Sponsor</b>: <br/>
|
|||
|
Aquilon Pharmaceuticals S.A.<br/><b>Not yet recruiting</b></p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Dietary Supplement: Artemisinin; Drug: Dexamethasone<br/><b>Sponsors</b>: Mateon Therapeutics; Windlas Biotech Private Limited<br/><b>Completed</b></p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: Inactivated COVID-19 Vaccine; Biological: Controlled vaccine<br/><b>Sponsor</b>: Sinovac Research and Development Co., Ltd.<br/><b>Recruiting</b></p></li>
|
|||
|
</ul>
|
|||
|
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
|
|||
|
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
|
|||
|
<ul>
|
|||
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>자외선살균등</strong> - 본 발명은 사람의 의복이나 사용한 마스크 등에 부착하여 있다 호흡기로 유입되어 감염을 유발할 수 있는 COVID-19와 같은 유해균류를 간편하게 살균하기 위한 휴대용 자와선살균등에 관한 것이다. 반감기가 길고 인체에 유해한 오존을 발생하지 않으면서 탁월한 살균능력이 있는 250~265nm(최적은 253.7nm) 파장의 자외선을 발광하는 자외선램프를 본 발명의 막대형의 자외선살균등 광원으로 사용하고 비광원부를 손으로 잡고 의복이나 사용한 마스크 등 유해균류가 부착되었을 것으로 의심되는 곳에 자외선을 조사하여 간편하게 유해균류를 살균하므로써 감염을 예방하기 위한 휴대용 자외선살균등에 관함 것이다. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=KR332958765">link</a></p></li>
|
|||
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Cabina de desinfección de doble carga exterior</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=ES331945699">link</a></p></li>
|
|||
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Camellia nitidissima C.W.Chi Caffeine and Chlorogenic acid composition for anti-SARS-CoV-2 and preparation method and application thereof</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU331907401">link</a></p></li>
|
|||
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Novel Method COVID -19 infection using Deep Learning Based System</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU331907400">link</a></p></li>
|
|||
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>EMPUNADURA DE RAQUETA O PALA PARA JUEGO DE PELOTA CON DISPENSADOR LIQUIDO POR CAPILARIDAD INSERTADO</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=ES331563132">link</a></p></li>
|
|||
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A SYSTEM AND METHOD FOR COVID- 19 DIAGNOSIS USING DETECTION RESULTS FROM CHEST X- RAY IMAGES</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU330927328">link</a></p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>System zum computergestützten Nachverfolgen einer von einer Person durchzuführenden Prozedur</strong> -
|
|||
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
Ein System (2000) zum computergestützten Nachverfolgen einer von einer Person (1) durchzuführenden Testprozedur, insbesondere für einen Virusnachweistest, bevorzugt zur Durchführung eines SARS-CoV-2 Tests, wobei das System (2000) umfasst:</p></li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">eine Identifizierungseinheit eines Endgeräts (30), die eingerichtet ist zum Identifizieren (201) der Person</li>
|
|||
|
</ul>
|
|||
|
<ol type="1">
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">unmittelbar vor einem Durchführen der Testprozedur durch die Person (1);</li>
|
|||
|
</ol>
|
|||
|
<ul>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">wobei die Identifizierungseinheit des Endgeräts (30) weiter eingerichtet ist zum Identifizieren (202) zumindest eines Testobjekts (20), bevorzugt einer Testkassette, insbesondere für einen SARS-CoV-2 Test, mehr bevorzugt eines Teststreifens, weiter bevorzugt ein Reagenz in einem Behälter, weiter bevorzugt eines Testsensors, unmittelbar vor der Durchführung der Testprozedur, die Identifizierungseinheit aufweisend:</li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">eine Kamera (31) des Endgeräts (30), eingerichtet zum Erfassen (2021) eines Objektidentifizierungsdatensatzes (21) als maschinenlesbaren Datensatz; und</li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">eine Auswerteeinheit (33) des Endgeräts (30), eingerichtet zum Vergleichen (2022) des erfassten Objektidentifizierungsdatensatzes (21) mit einem Objektdatensatz</li>
|
|||
|
</ul>
|
|||
|
<ol start="420" type="1">
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">eines Hintergrundsystems (40);</li>
|
|||
|
</ol>
|
|||
|
<ul>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">eine Nachverfolgungseinheit des Endgeräts (30), die eingerichtet ist zum Nachverfolgen (203) einer oder mehrerer Positionen der Person (1) während der Durchführung der Testprozedur mittels Methoden computergestützter Gesten- und/oder Muster- und/oder Bilderkennung mittels eines Prüfens, ob beide Hände (12) der Person (1) während der gesamten Durchführung der Testprozedur in einem vordefinierten Bereich oder einem von der Kamera (31a) des Endgeräts (30) erfassbaren Bereich sind;</li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">die Nachverfolgungseinheit des Endgeräts (30), zudem eingerichtet zum Nachverfolgen (203) von einer oder mehreren Positionen des zumindest einen Testobjekts (20) anhand der Form des Objekts während der Durchführung der Testprozedur mittels Methoden computergestützter Gesten- und/oder Muster- und/oder Bilderkennung; und</li>
|
|||
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">einer Anzeigeeinheit (34) des Endgeräts, eingerichtet zum Anleiten (204) der Person (1) zum Durchführen der Testprozedur während der Durchführung der Testprozedur.</li>
|
|||
|
</ul>
|
|||
|
<img alt="embedded image" id="EMI-D00000"/>
|
|||
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
|||
|
<ul>
|
|||
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE333370869">link</a></p></li>
|
|||
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Mascarilla impermeable</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=ES329916792">link</a></p></li>
|
|||
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法</strong> - 本申请公开了一种基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法。具体而言,本公开中提供了一种在其细胞膜表面展示新型冠状病毒SARS‑CoV‑2刺突蛋白S的细胞,包含所述细胞的针对新型冠状病毒SARS‑CoV‑2的疫苗或疫苗组合,所述细胞在制备用于预防或治疗新型冠状病毒SARS‑CoV‑2的疫苗中的应用及其制备方法。本公开的细胞和疫苗能够在体内高效活化B细胞,诱导中和抗体应答,在预防和降低新冠病毒感染中有广泛的应用前景。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN332882580">link</a></p></li>
|
|||
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>硫代咪唑烷酮药物在治疗COVID-19疾病中的用途</strong> - 本发明属于医药技术领域,具体涉及一种硫代咪唑烷酮药物或其药学上可接受的盐在制备用于治疗ACE2和TMPRSS2蛋白失调相关疾病的药物中的用途,尤其是在制备用于治疗COVID‑19疾病的药物中的用途。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN332882591">link</a></p></li>
|
|||
|
</ul>
|
|||
|
|
|||
|
|
|||
|
<script>AOS.init();</script></body></html>
|